Publications by authors named "Neeta B Amin"

Claim this Profile
E
Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor.
Manoli Vourvahis, Arthur J Bergman, Adam G Ogden, Jim Hughes, James R Gosset, Neeta B Amin

J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study.
Vincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, Amanda Darekar, Frank Tacke

Lancet Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging-Proton Density Fat Fraction.
Santos Carvajal-Gonzalez, Theresa Tuthill, Vincent Wai-Sun Wong, Amy Lauren Ashworth, Zeid Kayali, Neeta B Amin

Gastro Hep Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.
Jim H Hughes, Neeta B Amin, Jessica Wojciechowski, Manoli Vourvahis

CPT Pharmacometrics Syst Pharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
Neeta B Amin, Robert Frederich, Nikolaos Tsamandouras, Amina Z Haggag, Tilman Schuster

Diabetes Obes Metab· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualified kidney injury biomarkers demonstrate value during early clinical drug development.
Kodihalli C Ravindra, Kelly A Fader, David Potter, Zaher A Radi, Gary S Friedman, Neeta B Amin

Toxicol Sci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
Pitchumani Sivakumar, Michelle Saul, Douglas Robinson, Lindsay E King, Neeta B Amin

Sci Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
Neeta B Amin, Aditi R Saxena, Veena Somayaji, Robert Dullea

Clin Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
Neeta B Amin, Amanda Darekar, Quentin M Anstee, Vincent Wai-Sun Wong, Frank Tacke

BMJ Open· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.
Tim F Ryder, Arthur Bergman, Amanda King-Ahmad, Neeta B Amin, Manjinder S Lall

Xenobiotica· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
Roberto A Calle, Neeta B Amin, Santos Carvajal-Gonzalez, Trenton T Ross, Arthur Bergman

Nat Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, David L Cutler, Neeta B Amin

Clin Pharmacokinet· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.
Arthur Bergman, Santos Carvajal-Gonzalez, Sanela Tarabar, Aditi R Saxena, William P Esler, Neeta B Amin

Clin Pharmacol Drug Dev· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
Neeta B Amin, Santos Carvajal-Gonzalez, Julie Purkal, Tong Zhu, Collin Crowley

Sci Transl Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
William S Denney, Douglas S Denham, Michael R Riggs, Neeta B Amin

Clin Pharmacol Drug Dev· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.
Raman Sharma, John Litchfield, Karen Atkinson, Heather Eng, Neeta B Amin

Drug Metab Dispos· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of i.v. haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs.
Saeed Rasty, Neeta B Amin, Hani N Sabbah, Takayuki Mishima, Steven Borzak

Chest· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis